Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.

Abstract excerpt

With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients. The integration of the next generation of proteasome inhibitors and antibody therapeutics promise continued improvements in therapy with the expectation of consistent depth of response not quantifiable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alleles
• Share to High-Throughput Nucleotide Sequencing
• Share to Multimodal Imaging